CMS seeks comments on leadless cardiac pacemakers

The Centers for Medicare & Medicaid Services (CMS) announced on May 18 that it was initiating a national coverage analysis for leadless cardiac pacemakers.

In April, the FDA approved Medtronic’s Micra Transcatheter Pacing System, which is the first commercially available leadless intracardiac transcatheter pacing system in the U.S.

The public can make comments on the leadless pacemakers through June 17, according to CMS. It expects to complete the national coverage analysis by Feb. 16, 2017. CMS will assess the comments and evidence to establish a national coverage determination for coverage of the leadless pacemakers for Medicare and Medicaid patients.

“CMS considers all public comments, and is particularly interested in clinical studies and other scientific information relevant to the topic under review,” the agency said.

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.